The new refined minnesota risk score for acute graft-versus-host disease predicts overall survival and non-relapse mortality after T cell-replete haploidentical stem cell transplant with post-transplant cyclophosphamide

[1]  N. Kröger,et al.  MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD. , 2018, Blood.

[2]  Shannon R. McCurdy,et al.  Plasma-derived proteomic biomarkers in human leukocyte antigen-haploidentical or human leukocyte antigen-matched bone marrow transplantation using post-transplantation cyclophosphamide , 2017, Haematologica.

[3]  Sonali M. Smith,et al.  Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  M. Robin,et al.  A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[5]  R. Bouabdallah,et al.  Nonmyeloablative conditioning, unmanipulated haploidentical SCT and post-infusion CY for advanced lymphomas , 2014, Bone Marrow Transplantation.

[6]  T. Braun,et al.  A Biomarker-Based Grading System At Onset Of GvHD Predicts NRM Better Than The Modified Glucksberg Grading System , 2013 .

[7]  J. Wingard,et al.  First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[8]  M. MacMillan,et al.  The best endpoint for acute GVHD treatment trials. , 2010, Blood.

[9]  J. Klein,et al.  IBMTR Severity INDEX FOR GRADING ACUTE GRAFT‐VERSUS‐HOST DISEASE: RETROSPECTIVE COMPARISON WITH GLUCKSBERG GRADE , 1997, British journal of haematology.

[10]  S. Burdach,et al.  Treatment of acute graft-versus-host disease with methylprednisolone and cyclosporine with or without an anti-interleukin-2 receptor monoclonal antibody. A multicenter phase III study. , 1995 .

[11]  E D Thomas,et al.  1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.

[12]  P. Neiman,et al.  CLINICAL MANIFESTATIONS OF GRAFT‐VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL‐A-MATCHED SIBLING DONOR,S , 1974, Transplantation.

[13]  T. Braun,et al.  A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study. , 2015, The Lancet. Haematology.

[14]  A. Rashid,et al.  Prognostic value of response after upfront therapy for acute GVHD , 2012, Bone Marrow Transplantation.